He also noted that the effect of drugs on gray matter atrophy might be of interest to researchers. However, not enough data are available to draw conclusions.
Looking forward, he suggested that gray matter atrophy may play an important role in future clinical trials. “I believe gray matter atrophy is an attractive outcome measure for MS clinical trials, because it seems to be very important, it’s feasible, and I think it should be fairly straightforward,” concluded Dr. Rudick.
—Lauren LeBano